Press Release: OBIO CAAP Companies Raise More Than $109 Million in Investments

Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit membership based organization that is Ontario’s leading advocate for the health science industry, announced today that Ontario health science companies that have participated in its Capital Access Advisory Program (CAAP®) have raised more than $109 Million since the CAAP program launched in 2013.

Springboard’s Health Innovation Hub: 2018 Applications Now Open

Springboard’s Health Innovation Hub is a program for women-led life science and digital health companies seeking seed and growth funding and expert connections. The program runs in two tracks: Life Science and Digital Health.

Selected companies will be matched with a team of relevant, targeted advisors and participate in several in-person and virtual workshops and presentation sessions throughout the year that provide exposure to influencers, active investors, and potential strategic partners.

New Funding Available: HealthBound II - Improve Patient Wait Times in an Outpatient Clinic at St. Michael's

The Biomedical Zone has opened up applications for HealthBound II, aimed at finding a solution to improve patient wait times in an outpatient clinic at St. Michael's.

  • The winning company will receive:
  • A cash prize of $5000
  • Residency in the Biomedical Zone
  • A subsidized pilot opportunity at St. Michael's 
  • Mentorship and immersion from clinicians, hospital administrators, and IT

Qvella Raises US$20M in Series B Financing to Fund Clinical Trials, On-Going Research, Team Expansion, and Manufacturing Buildup

December 4, 2017 – Qvella, a leading molecular diagnostics company closed US$20 million in Series B financing. The funding round was co-led by Qvella’s existing investor syndicate – including RA Capital, Whitecap Venture Partners, Hatteras Ventures, and Sands Capital – and new strategic investor bioMérieux, a world leader in the field of in vitro diagnostics. The proceeds will be used to fund clinical trials, to support on-going research and development, and to facilitate team expansion and manufacturing scale-up.

Thornhill Research & Rostrum Medical Announce Technology Development Agreement

TORONTO, ON  Thornhill and Rostrum celebrate the finalization of a Technology Development Agreement which includes the licensing of certain Thornhill IP and an investment by Rostrum into Thornhill. This agreement is aimed to further Rostrum’s development of its Pulmonary Health Monitoring during ventilation, in ICU, OR and ER applications while supporting Thornhill’s commercialization efforts of their own innovative products.